AnteoTech (ASX:ADO): Cash Position and Battery Trials Shape September Update

Aditi Sarkar

29 October 2026 05:11 PM AEDT

AnteoTech (ASX:ADO): Cash Position and Battery Trials Shape September Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cash and equivalents were approximately A$11.0m at the end of September 2026.
An R&D tax refund materially affected the reported operating cash outflow.
Battery-material sampling and separator development continued across several programmes.
Life-sciences customer arrangements and product validation also progressed.

AnteoTech Ltd (ASX:ADO) develops specialty materials for batteries alongside products used in life-sciences applications. Its September 2026 update combined cash-flow disclosures with ongoing technical evaluations, sample deliveries and commercial discussions across both businesses. The timing of research tax receipts is important when interpreting the reported quarter.

Cash and the Research Tax Receipt

AnteoTech (ASX:ADO) reported approximately A$11.0m in cash and equivalents at 30 September 2026, including A$5.5m on a six-month term deposit maturing on 18 December 2026. Its net operating cash outflow was A$28k. That low reported outflow included A$1,905,639 of research and development tax incentive refunds, rather than reflecting the normal difference between customer receipts and spending. Without that receipt, the operating cash outflow would have been approximately A$1.93m.

Reading the Quarterly Cash Movements

Customer receipts totalled A$200,134, including A$134,138 from a life-sciences customer. Investing outflow was A$135k and financing outflow A$41k. AnteoTech (ASX:ADO) reported no undrawn banking facilities and no bank debt apart from lease and asset-finance liabilities. Its filing contains inconsistent ending-cash figures: A$11,201k appears in one line while A$10,997k appears in the cash reconciliation. The latter aligns with the component balances, so the approximate A$11.0m figure provides a more reliable summary than suggesting unwarranted precision.

Separator and Battery-Material Evaluations

In battery materials, AnteoTech (ASX:ADO) reported a binding strategic collaboration and sales arrangement for Xerabrid, a ceramic-coated separator using Anteo S. Seven prospective customers requested samples, with delivery expected before the end of 2026. A further 40 litres of Anteo S was delivered to one customer for trials. Discussions about future supply were also reported for Anteo C after cumulative volumes supplied in Asia reached 45 litres. Sample requests and trials demonstrate engagement but do not establish future product volumes or committed recurring income.

Silicon Anodes and Cell Testing

A United States consumer-electronics manufacturer requested a quotation covering 30 litres of SiMRAX for scale-up evaluation. The company also assembled and tested its first Ultranode 95 18650 cylindrical cells and continued negotiations over two non-exclusive joint development agreements. Separately, Ultranode 70 was reported to achieve 500 cycles with 70 per cent capacity retention in commercial-format cells, without an identified end customer. For AnteoTech (ASX:ADO), these developments remain technical or negotiation-stage milestones rather than evidence of concluded supply contracts.

Diagnostics and Corporate Milestones

In life sciences, the company reported an existing five-year take-or-pay supply arrangement and anticipated a further order before the end of 2026. A next stage of an immunoassay development programme is under way, while independent validation of AnteoBind NXT was commissioned in the United States and United Kingdom. AnteoTech (ASX:ADO) also reported planned finance leadership changes, with Luke Oxenham scheduled to commence on 23 November 2026 and Scott Waddell expected to depart on 4 December 2026. The term deposit matures in December and a research programme milestone was extended to May 2027.

Commercial and Funding Dependencies

The update does not demonstrate that evaluation programmes have converted into material recurring sales. Customer receipts remained considerably below spending before the research tax refund, while new battery products depend on qualification and customer decisions. The company has reported multiple samples, negotiations and development stages, each with different degrees of commercial certainty. This distinction is central to interpreting both the cash balance and the product pipeline.

Key Insights

AnteoTech (ASX:ADO) entered the final quarter of 2026 with cash reserves and active development programmes across batteries and diagnostics. The research tax refund materially changed its reported operating cash flow, while successful technical testing has not yet established recurring product demand.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.